Business Wire

DirectMed Parts & Service Expands Internationally; Announces Partnership with LBN Medical

Share

DirectMed Parts & Service (“DirectMed”), a portfolio company of NMS Capital (“NMS”), announced today that it has acquired LBN Medical (“LBN” or the “Company”). Terms of the transaction were not disclosed.

Headquartered in Aalborg, Denmark, LBN is a leading reseller of aftermarket diagnostic imaging equipment to customers around the world. LBN sells complete systems and parts covering more than fifteen brands, including major OEMs such as Canon, GE, Hologic, Siemens, and Philips. The Company was founded in 2003 by CEO Lars Braun Nielsen and has since grown to more than 50 employees at facilities in Denmark and Egypt.

Lars Braun Nielsen, CEO and Founder of LBN, stated, “Brad and the DirectMed team have outlined their mission to extend the life of medical imaging equipment to improve access, reduce waste, and lower healthcare costs. We are thrilled to be a part of this endeavor, and to work with the DirectMed team and NMS to accelerate our growth. The partnership with DirectMed provides LBN with tremendous resources to provide an even higher level of service and expertise to our customers, including a greater breadth and depth of parts and technical support.”

“We have known LBN Medical for several years and believe they are the logical company to help DirectMed expand our parts business outside of North America. Their distribution team – which speaks 21 different languages, with sales history in over 60 countries, and employs experts across seven modalities – is the perfect complement to our business,” said Brad de Koning, DirectMed’s President & CEO. “Acquiring LBN Medical begins an exciting new chapter for DirectMed, with the addition of system sales to our customer base, and for LBN Medical, who will now stock and have access to over 10,000 unique part numbers to support theirs.”

David Peterson, Managing Director at NMS, stated, “Since we partnered with the DirectMed team in June 2021, one of our primary areas of focus has been expanding our geographic coverage. Providers around the world are looking for cost-effective solutions to acquire and maintain equipment as they continue to grow their practice. The combination of DirectMed and LBN supports that exact need in the marketplace. We are very excited to be partnering with the LBN team for the next phase of our business and look forward to leveraging DirectMed’s experience in parts and related repairs to accelerate our growth internationally.”

Accura and Greenberg Traurig provided legal advice to DirectMed.

About LBN:
LBN Medical is a leading reseller of aftermarket medical imaging equipment to customers around the world. LBN sells equipment and parts covering more than fifteen brands, including major OEMs such as Canon, GE, Siemens, and Philips. The Company was founded in 2003 by CEO Lars Braun Nielsen, and has since grown to an organization of more than 50 associates at facilities in Denmark and Egypt. For additional information on LBN, please visit the firm's website at LBNmedical.com.

About DirectMed:
DirectMed Parts & Service is the largest independent diagnostic imaging parts supplier specializing in MRI and CT machines with over 60,000 parts in stock. An ISO 13485 certified company, DirectMed repairs, supports and sells GE, Siemens, and Philips parts to healthcare networks, imaging centers and independent service organizations ("ISOs") around the world. For additional information on DirectMed, please visit the firm's website at directmedparts.com.

About NMS Capital:
NMS Capital is a New York headquartered private investment firm specializing in strategic equity investments and leveraged buyouts of lower middle market companies. The firm was formed through the spin-out of a group of portfolio companies from Goldman Sachs’ Merchant Banking Division. NMS focuses on companies headquartered in the U.S. poised to benefit from sustainable growth trends with particular concentration on companies in Business Services and Healthcare Services. For additional information on NMS, please visit the firm's website at nms-capital.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

David Peterson
Managing Director
dpeterson@nms-capital.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

KAYTUS Unveils Upgraded MotusAI to Accelerate LLM Deployment12.6.2025 14:11:00 EEST | Press release

KAYTUS, a leading provider of end-to-end AI and liquid cooling solutions, today announced the release of the latest version of its MotusAI AI DevOps Platform at ISC High Performance 2025. The upgraded MotusAI platform delivers significant enhancements in large model inference performance and offers broad compatibility with multiple open-source tools covering the full lifecycle of large models. Engineered for unified and dynamic resource scheduling, it dramatically improves resource utilization and operational efficiency in large-scale AI model development and deployment. This latest release of MotusAI is set to further accelerate AI adoption and fuel business innovation across key sectors such as education, finance, energy, automotive, and manufacturing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612546292/en/ MotusAI Dashboard As large AI models become increasingly embedded in real-world applications, enterprises are

FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 202512.6.2025 14:00:00 EEST | Press release

Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for zoliflodacin, an investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adults and pediatric patients 12 years and older. The FDA assigned a target action date of December 15, 2025 under the Prescription Drug User-Fee Act (PDUFA). It is expected the FDA will notify Innoviva Specialty Therapeutics regarding the FDA’s decision to conduct an Advisory Committee Meeting in the Day 74 letter. If approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades. The U.S. FDA has granted zoliflodacin a Qualified Infectious Disease Product (QIDP) designation. This designation allows it to benefi

Supply Chain Leaders to Share Perspective on Tackling Tariffs, Trade, and Disruption During Exclusive Digital Event12.6.2025 14:00:00 EEST | Press release

As global trade tensions remain at the forefront of business decision-making,Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, will host technology and life sciences supply chain leaders for a special tariff-focused digital event with economic futurist Andrew Busch on June 17, 2025 at 11:00am eastern. Titled, Tariffs, Trade, and Turbulence: How to Respond to Today’s Supply Chain Challenges, the event is tailored for global business leaders and will offer expert insights on how to navigate today’s volatile trade environment with modern supply chain solutions to build resilient, future-ready supply chains. “We’re witnessing a seismic reshaping of global trade dynamics with leaders needing to decode the economic and geopolitical forces behind tariff policy while being able to anticipate what’s coming next,” said Andrew Busch, economic futurist and economist at AndrewBusch.com. “Tariffs are no longer just a policy lever; they’re a strategic force reshaping the g

BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 202512.6.2025 13:00:00 EEST | Press release

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will present new clinical data from three cornerstone hematology assets at the European Hematology Association (EHA) Congress. Four oral presentations highlight the promising clinical activity of BeOne’s next-generation BCL2 inhibitor sonrotoclax, BTK protein degrader BGB-16673, and the backbone of our hematology franchise, BTK inhibitor BRUKINSA (zanubrutinib), which has the broadest label globally of any approved BTK inhibitor. These data reinforce the company’s strategic vision to redefine the standard of care for B-cell malignancies. “The data presented at EHA 2025 underscore the strength of BeOne’s comprehensive hematology pipeline, built on the success of BRUKINSA, the only BTK inhibitor to demonstrate superior progression-free survival over ibrutinib in a Phase 3 trial,1” said Lai Wang, Ph.D. Global Head of R&D at BeOne. “With our potentially best-in-class BCL2 inhibitor, sonrotoclax, and fi

Infobip Named Among Top 75 in Fortune’s Europe’s Most Innovative Companies 202512.6.2025 11:17:00 EEST | Press release

Global communications platform Infobiphas been recognized among the top 75 companies in Fortune’s inaugural ranking of Europe’s Most Innovative Companies for 2025. It holds the position of number 68, placing it in the top 25% of all listed companies. This distinction reflects Infobip’s ongoing commitment to advancing Europe’s IT sector and digital infrastructure through cutting-edge innovation. The first Fortune Europe’s Most Innovative Companies list, created in collaboration with Statista, evaluated 300 companies from 21 countries and 16 industries based on innovation culture, product development, and process improvements. Infobip is at the forefront of Europe’s digital transformation. Infobip participates in the IPCEI-CIS project, which aims to build the next-generation global communications platform, thereby reinforcing Europe’s competitiveness in the tech sector. Infobip’s involvement in the IPCEI-CIS project, along with partnerships with Deutsche Telekom AG, NVIDIA, Telefónica, a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye